• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

    5/30/23 5:30:57 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SHPH alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ________)*

     

    SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

     

    (Name of Issuer)

     

    Common Stock, $0.00001 par value per share

     

    (Title of Class of Securities)

     

    825693

     

    (CUSIP Number)

     

    Amir F. Heshmatpour

    17304 Preston Road, Suite 300

    Dallas, Texas 75252

    (310) 721-4391

     

    With copies to:

     

    Larry Friedman

    Friedman & Feiger LLP

    17304 Preston Road, Suite 300

    Dallas, Texas 75252

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    March 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 825693   13G  

    Page 2 of 6 Pages

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    AFH Holding & Advisory, LLC (EIN – 20-3429148) – Amir F. Heshmatpour

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    909,581

    6.

    SHARED VOTING POWER

    352,215

     

    7.

    SOLE DISPOSITIVE POWER

     

    909,581

    8.

    SHARED DISPOSITIVE POWER

     

    352,215

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,261,796

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.14%

     

     

     

     

    CUSIP No. 825693   13G  

    Page 3 of 6 Pages

     

    Item 1.

     

      (a)

    Name of Issuer

     

    This statement on Schedule 13G (this “Schedule 13G”) relates to the shares of common stock, par value $0.00001 per share (the “Shares”), of Shuttle Pharmaceutical Holding, LLC (the “Company”).

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    The Company is a Maryland corporation with its principal executive offices located at One Research Court, Suite 450, Rockville, Maryland 20850.

     

    Item 2.

     

      (a)

    Name of Person Filing

     

    AFH Holding & Advisory, LLC

         
      (b)

    Address of the Principal Office or, if none, residence

     

    17304 Preston Road, Suite 300, Dallas, Texas 75252

         
      (c)

    Citizenship

     

    United States

         
      (d)

    Title of Class of Securities

     

    Shares of Common Stock

         
      (e)

    CUSIP Number

     

    825693

     

     

     

     

    CUSIP No. 825693   13G   Page 4 of 6 Pages

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 1,261,796
         
      (b) Percent of class: 9.14%
         
      (c) Number of shares as to which the person has:
           
        (i) Sole power to vote or to direct the vote 909,581.
           
        (ii) Shared power to vote or to direct the vote 352,215.
           
        (iii) Sole power to dispose or to direct the disposition of 909,581.
           
        (iv) Shared power to dispose or to direct the disposition of 352,215.

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐ .

     

    Instruction. Dissolution of a group requires a response to this item.

     

     

     

     

    CUSIP No. 825693   13G   Page 5 of 6 Pages

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8. Identification and Classification of Members of the Group.

     

      (i) 909,581 shares of common stock held of record by AFH Holding & Advisory, LLC, of which Mr. Amir F. Heshmatpour is the sole member and over which he has sole voting and investment control, (ii) 234,215 shares of common stock help of record by KIG LLC of which Mr. Heshmatpour’s spouse, Kathy Heshmatpour, exercises sole voting and investment control, and (iii) 120,000 shares held by Angelina Heshmatpour, the minor daughter of Mr. Heshmatpour.

     

    Item 9. Notice of Dissolution of Group.

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 825693   13G   Page 6 of 6 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      05/30/2023
      Date
       
      /s/ Amir F. Heshmatpour
      Signature
       
      Amir F. Heshmatpour/President
      Name/Title

     

     

    Get the next $SHPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SHPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SHPH
    SEC Filings

    See more
    • Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

      5/15/25 4:25:17 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Shuttle Pharmaceuticals Holdings Inc.

      SCHEDULE 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

      5/15/25 3:53:02 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.

      10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

      5/8/25 5:29:46 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SHPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Cooper Chris

      3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

      4/2/25 8:00:25 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Nabyt Oleh claimed ownership of 184,162 shares (SEC Form 3)

      3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

      3/21/25 8:00:04 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Scorsis George claimed ownership of 184,162 shares (SEC Form 3)

      3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

      3/21/25 8:00:07 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SHPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Shuttle Pharmaceuticals Holdings Inc. (Amendment)

      SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

      10/17/23 6:57:47 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

      SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

      5/30/23 5:30:57 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SHPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SHPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

      GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

      6/4/25 4:01:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma Provides Corporate Update

      GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Shuttle Pharma's recent highlights: Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma highlights include: Patient enrollment nears milestone as nearly 50% enrollment has been achieved in the initial randomized portion of the trial.84% of the enrolled patients have completed all seven cycles.Ropidoxuridine is being reported as we

      5/15/25 4:45:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

      GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites reporting that the drug has been well tolerated and toxicity no greater than 2 on a scale of 1-5. Further, 84% of the enrolled patients have completed all seven cycles. Shuttle has begun anal

      5/8/25 4:01:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

      GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

      6/4/25 4:01:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

      GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of

      3/12/25 6:20:00 AM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

      GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer. The Company's current Chief Financial Officer, Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis. Mr. Lorber is a CPA with more than 40 years of profession

      6/18/24 9:00:00 AM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care